Results 141 to 150 of about 20,950 (257)

Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography

Journal of Clinical Rheumatology and Immunology
Background This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high-resolution peripheral quantitative computed tomography (HR-pQCT).
Yingzhao Jin, Isaac T Cheng, Ho So, Billy T Lai, Shirley K Ying, Kitty Y Kwok, James Griffith, Vivian Hung, Cheuk-Chun Szeto, Jack Jock-Wai Lee, Ling Qin, Lai-shan Tam   +11 more
doaj   +1 more source

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.
Georgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, Falk G. Bechara, Farida Benhadou, Joana Cabete, Raffaele Dante Caposiena Caro, Giovanni Damiani, Maia Delage Toriel, Veronique Del Marmol, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Evgeniya Hristakieva, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Niamh Kearney, Brian Kirby, Natalia Kirsten, Piotr K. Krajewski, Vesta Kucinskiene, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Francesca Prignano, Tadas Raudonis, Hans Christian Ring, Marco Romanelli, Samed Şahin, Ditte M. L. Saunte, Linnea Thorlacius, Thrasyvoulos Tzellos, Hessel H. Van Der Zee, Kelsey Van Straalen, Christos C. Zouboulis   +41 more
wiley   +1 more source

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis:Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors [PDF]

, 2019
Objective: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi).
Antolini, Christopher, Azevedo, Valderilio, Barkham, Magnus, Barragan, Sergio Duran, Berman, Alberto, Blasco, Francisco Navarro, Blicharski, Tomasz, Brzezicki, Jan, Burmester, Gerd, Carlier, Hilde, Carrio, Judith, Cocco, Jose Maldonado, Collantes, Eduardo, Combe, Bernard, Cons‐Molina, Fidencio, Cortes‐Maisonet, Gregorio, Deodhar, Atul, Dudek, Anna, Elkayam, Ori, Fernandez, Carlos Gonzalez, Flint, Kathleen, Gaffney, Karl, Galeazzi, Mauro, Gaylis, Norman, Goddard, David, Goupille, Philippe, Greenwald, Maria, Gremese, Elisa, Hong, Seung Jae, Howell, Mary, Hrycaj, Pawel, Ince, Akgun, Jesus, Amarilis Perez‐De, Ju, Ji Hyeon, Järvinen, Pentti, Kaine, Jeffrey, Kang, Seong Wook, Keiserman, Mauro, Kim, Tae‐Hwan, Kivitz, Alan, Klein, Steven, Kremer, Joel, Krishnan, Eswar, Lee, Chang Keun, Lee, Eun Bong, Lee, Sang Heon, Lee, Sang‐Hoon, Lespessailles, Eric, Li, Xiaoqi, Lidman, Roger, Loveless, James, Lucero, Eleonora, Marcolino, Flora, Mariette, Xavier, Masmitja, Jordi Gratacos, Mehta, Daksha, Morin, Frederic, Moscovici, Yolanda, Mueller, Eric, Mysler, Eduardo, Nguyen, Minh,, Pacheco‐Tena, Cesar, Pantojas, Carlos, Park, Min‐Chan, Peters, Eric, Plebanski, Rafal, Poddubnyy, Denis, Querubin, Roel, Rahman, Proton, Reitblat, Tatiana, Remus, Cesar Ramos, Reveille, John, Rivera, Tania, Rodriguez, Aaron Alejandro Barrera, Rodriguez, Juan Cruz Rizo, Salvarani, Carlo, Sanchez‐Burson, Juan, Sande, Marleen, Santisteban, Silvia, Sayers, Michael, Scotton, Antonio, Scoville, Craig, Shaw, David, Shin, Kichul, Singhal, Atul, Skinner, Cassandra, Soto‐Raices, Oscar, Soubrier, Martin, Szymanska, Malgorzata, Thai, Christine, Wells, Alvin, Wojciechowski, Rafal, Xavier, Ricardo,, Ximenes, Antonio, Zhao, Fangyi, Zisman, Devy   +95 more
core   +6 more sources

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Hair follicles (HFs) were extracted from skin biopsies. From these, original sequencing data were obtained and integrated with two independent studies to build a HF single‐cell transcriptomic atlas. It enabled delineating the fate of HF stem cells.
Audrey Onfroy, Francette Jean‐Louis, Philippe Le Corvoisier, Fanny Coulpier, Kévin Muret, Eric Bonnet, Raphaele Arrouasse, Caroline Boucle, Salwa Abid, Emilie Sbidian, Christina Bergqvist, Pierre Wolkenstein, Véronique Godot, Jean‐François Deleuze, Yves Lévy, Piotr Topilko, Etienne Audureau, Sophie Hue   +17 more
wiley   +1 more source

Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study [PDF]

Vestnik Dermatologii i Venerologii
Background. IL-17 blockers have expanded the possibilities of psoriasis therapy. Their high efficacy and safety profile have been demonstrated in phase I–III studies and in real-world clinical practice.
Arfenya E. Karamova, Anastasiia A. Vorontsova, Olga G. Artamonova   +2 more
doaj   +1 more source

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]

, 2019
Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos, Navarro-Artieda, Ruth, Sicras-Mainar, Antoni   +2 more
core   +2 more sources

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.

JAMA dermatology, 2022
Zenas Z N Yiu, G. Becher, B. Kirby, P. Laws, N. Reynolds, Catherine H. Smith, R. Warren, C. Griffiths   +7 more
semanticscholar   +1 more source

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis

Case Reports in Gastrointestinal Medicine, 2018
Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for ...
Dean Ehrlich, Nimah Jamaluddin, Joseph Pisegna, David Padua   +3 more
doaj   +1 more source

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)

Rheumatology and Therapy
Introduction Long-term treatment of psoriatic arthritis (PsA) is required to prevent progression. However, persistence with current treatments is challenging due to tolerability and acceptability issues. The objective of this study was to estimate 1-year
Hideto Kameda, Kentaro Ishii, Junna Kiriyama, Toshiaki Mikami, Hideya Uratsuji, Akimichi Morita   +5 more
doaj   +1 more source